Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABIO Nasdaq 2834 http://arcabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arca Biopharma Inc

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 - Jul 13th, 2021 12:00 pm
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th - Jul 9th, 2021 12:00 pm
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 - Jul 8th, 2021 3:20 pm
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement - Jul 7th, 2021 12:00 pm
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update - May 11th, 2021 8:15 pm
Christopher Graybill Joins ARCA as Vice President, Clinical Development - May 5th, 2021 8:05 pm
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer - May 3rd, 2021 8:30 pm
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update - Mar 18th, 2021 8:30 pm
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation - Feb 13th, 2021 6:09 am
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Dec 15th, 2020 1:30 pm
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders - Dec 9th, 2020 10:40 pm
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Nov 23rd, 2020 1:30 pm
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Nov 2nd, 2020 1:30 pm
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 - Oct 7th, 2020 12:30 pm
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality - Oct 5th, 2020 8:30 pm
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 - Sep 21st, 2020 12:00 pm
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth - Aug 17th, 2020 12:49 pm
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 - Aug 12th, 2020 12:00 pm
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update - Aug 5th, 2020 8:15 pm